Organoids take on ESCC’s toughest tumours
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
List view / Grid view
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
Researchers have identified the process behind cancer cell energy production, providing a drug target for treatments to inhibit growth.
By stimulating a patient’s immune system, a drug already in use to treat a blood disorder can prevent the growth of a variety of solid tumours...